Low-Dose Cyclophosphamide–Fludarabine Conditioning for T Cell Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current T cell therapies face challenges in predicting effectiveness due to the use of high-dose, toxic, and non-specific chemotherapy drugs, leading to painful and sometimes deadly adverse events, necessitating an improved preconditioning regimen.

Innovation Solution

Administering cyclophosphamide and fludarabine at specific doses (200 mg/m2/day to 2000 mg/m2/day and 20 mg/m2/day to 900 mg/m2/day, respectively, to condition patients for T cell therapy, reducing endogenous lymphocytes, increasing serum levels of homeostatic cytokines, and enhancing T cell efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If high-dose chemotherapy drugs are administered to condition patients for T cell therapy, then the effectiveness of T cell therapy is improved, but toxic and non-specific adverse events increase

Engineering Contradiction:

Improveeffectiveness of T cell therapyVSAvoidtoxic and non-specific adverse events

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the dosing parameters of chemotherapy drugs from high doses to low doses (cyclophosphamide 200-2000 mg/m2/day and fludarabine 20-900 mg/m2/day), transforming the conditioning approach to achieve T cell efficacy while minimizing toxicity. This parameter change resolves the contradiction by finding an optimal dose range that provides sufficient lymphocyte reduction without causing severe adverse events

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent applies partial action by using sub-lethal doses of chemotherapy drugs that partially reduce endogenous lymphocytes rather than completely depleting them. This partial reduction is sufficient to improve T cell therapy efficacy while avoiding the toxic effects associated with complete lymphocyte ablation

Inventive Principle:

Principle #16Partial or excessive action

2Quantity of substance

If high-dose chemotherapy drugs are administered to condition patients, then endogenous lymphocytes are reduced, but painful and deadly adverse events occur

Engineering Contradiction:

Improveendogenous lymphocytesVSAvoidpainful and deadly adverse events

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The patent changes the dosage parameters to low-dose ranges (cyclophosphamide 200-2000 mg/m2/day and fludarabine 20-900 mg/m2/day), achieving sufficient lymphocyte reduction for T cell therapy efficacy while staying below the threshold for severe toxic effects

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent applies preliminary action by administering low-dose chemotherapy conditioning before T cell infusion to create an optimal microenvironment. This preliminary lymphocyte reduction prepares the patient's immune system to better accept and respond to the transferred T cells without exposing the patient to excessive toxicity

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS12458654B2Methods of conditioning patients for T cell therapy

Publication Date: 2025.11.04 KITE PHARMA INC

AI summary

The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.